Share

February 2015; 2 (1) Views & ReviewsOpen Access

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Scott S. Zamvil, Anthony J. Slavin
First published January 22, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000062
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
5465

Share

Article Information

vol. 2 no. 1 e62
DOI: 
https://doi.org/10.1212/NXI.0000000000000062
PubMed: 
25635259
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 24, 2014
  • Accepted in final form December 1, 2014
  • First Published January 22, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Scott S. Zamvil, MD, PhD and
    2. Anthony J. Slavin, PhD
  1. Scott S. Zamvil, MD, PhD and
    2. Scientific Advisory Boards:

    1. Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology, Neuroimmunology and Neuroinflammation, Associate Editor, 2011-present (2) Journal the Neurological Sciences, Associate Editor, 2011-present

    Patents:

    1. “Aquaporin-4 peptides and methods for using same” (SF2010-074; USF-461PRV (pending). The application describes the discovery of aquaporin-4 T cell determinants in neuromyelitis optica patients and the use for antigen-specific tolerance.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. SSZ has received honoraria for speaking engagements for Biogen-Idec, Teva-Neuroscience, and Genzyme.

    Consultancies:

    1. SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme and Novartis

    Speakers' Bureaus:

    1. Advanced Health Media, 2009-present Biogen Idec, 2009-present

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH RO1 AI073737 NIH RO1 NS 063008

    Research Support, Academic Entities:

    1. NMSS RG 4768A9/1 NMSS RG 5180A11/1

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation, PI Alexander M. and June L. Maisin Foundation, PI

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Anthony J. Slavin, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Anthony Slavin is currently an employee of Abbvie Bioresearch Center and was formerly an employee of Boehringer Ingelheim Pharmaceuticals

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Anthony Slavin is currently an employee of Abbvie Bioresearch Center and was formerly an employee of Boehringer INgelheim Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco; and Abbvie Bioresearch Center Inc. (A.J.S.), Worcester, MA.
  1. Correspondence to Dr. Zamvil: zamvil{at}ucsf.neuroimmunol.org
View Full Text

Article usage

Article usage: January 2015 to December 2021

AbstractFullPdfSource
Jan 2015489210184Highwire
Feb 201521514095Highwire
Feb 20150297233pmc
Mar 201512818572Highwire
Mar 20150190138pmc
Apr 20151073737Highwire
Apr 2015013285pmc
May 2015772027Highwire
May 20150134103pmc
Jun 2015763420Highwire
Jun 2015011472pmc
Jul 2015471821Highwire
Jul 201505848pmc
Aug 2015871228Highwire
Aug 201506742pmc
Sep 2015451914Highwire
Sep 201507450pmc
Oct 2015292823Highwire
Oct 201508350pmc
Nov 2015562114Highwire
Nov 201508458pmc
Dec 20151081414Highwire
Dec 201507738pmc
Jan 2016561518Highwire
Jan 201609359pmc
Feb 2016661522Highwire
Feb 201607855pmc
Mar 20161361226Highwire
Mar 201606943pmc
Apr 201672219Highwire
Apr 2016010943pmc
May 2016472119Highwire
May 201609827pmc
Jun 201658812Highwire
Jun 201604432pmc
Jul 2016561820Highwire
Jul 201604925pmc
Aug 20166159Highwire
Aug 201604934pmc
Sep 2016581424Highwire
Sep 201605138pmc
Oct 2016651411Highwire
Oct 201604632pmc
Nov 201656925Highwire
Nov 201605636pmc
Dec 2016411522Highwire
Dec 201604625pmc
Jan 2017541314Highwire
Jan 201707135pmc
Feb 201766925Highwire
Feb 201706129pmc
Mar 2017461318Highwire
Mar 201707225pmc
Apr 201753717Highwire
Apr 2017183538pmc
May 2017441457Highwire
May 2017425562pmc
Jun 2017461019Highwire
Jun 2017294953pmc
Jul 201739919Highwire
Jul 2017265461pmc
Aug 2017331324Highwire
Aug 2017245660pmc
Sep 2017431515Highwire
Sep 2017346469pmc
Oct 2017211011Highwire
Oct 2017355059pmc
Nov 201740929Highwire
Nov 20173891101pmc
Dec 201744624Highwire
Jan 2018105050Highwire
Feb 201875355Highwire
Mar 2018810049Highwire
Apr 201897237Highwire
Apr 2018236569pmc
May 20181212134Highwire
Jun 201869226Highwire
Jun 2018184448pmc
Jul 201898340Highwire
Aug 2018115850Highwire
Aug 2018183332pmc
Sep 201846148Highwire
Oct 201889670Highwire
Nov 201878636Highwire
Dec 2018833858Highwire
Jan 20191327236Highwire
Feb 20191739964Highwire
Mar 2019129658Highwire
Apr 20191010470Highwire
May 20191113070Highwire
Jun 20191319973Highwire
Jul 2019915251Highwire
Aug 20191537238Highwire
Sep 20191021152Highwire
Oct 20191320962Highwire
Nov 20191328735Highwire
Dec 2019911735Highwire
Jan 20201414556Highwire
Feb 2020812844Highwire
Mar 2020611454Highwire
Apr 2020510552Highwire
May 2020914063Highwire
Jun 2020411777Highwire
Jul 2020188234Highwire
Aug 202078135Highwire
Sep 20201039986Highwire
Oct 2020721330Highwire
Nov 20201010944Highwire
Dec 2020811026Highwire
Jan 20211712245Highwire
Feb 2021714633Highwire
Mar 20211017245Highwire
Apr 20211112858Highwire
May 20211116934Highwire
Jun 20211117835Highwire
Jul 2021717053Highwire
Aug 2021812136Highwire
Sep 20211114444Highwire
Oct 2021914157Highwire
Nov 20211513643Highwire
Dec 2021712239Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement